- Home
- SCPQ vs PLYX Comparison
SCPQ vs PLYX Comparison
Compare SCPQ & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCPQ | PLYX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.5M | 112.7M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SCPQ | PLYX |
|---|---|---|
| Price | $10.07 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 56.3K | 30.9K |
| Earning Date | 01-01-0001 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $1.85 |
| 52 Week High | $10.10 | $10.93 |
Technical Indicators
Market Signals| Indicator | SCPQ | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 44.37 |
| Support Level | $10.01 | $1.87 |
| Resistance Level | N/A | $2.18 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 70.59 | 51.74 |
Price Performance
Historical ComparisonAbout SCPQ Social Commerce Partners Corporation Class A Ordinary Shares
Social Commerce Partners Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.